LIFE - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma Fourth Quarter and Full Year 2020 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

As a reminder this conference is being recorded for replay purposes. It is now my pleasure to hand the conference call over to Ashlee Dunston, aTyr's Director of Investor Relations and Corporate Communications. Ms. begin. may you Dunston,

Ashlee Dunston

and to everyone. and discuss results XXXX operator, joining full you us operating update. corporate today aTyr's and good you, Thank afternoon, for year Thank fourth quarter

Jill Sanjay joined are President and today Dr. Broadfoot, We Shukla, CFO. our by and our CEO; Ms.

review including for or call, provide will ATYRXXXX the positioning our biology. research in questions. neuropilin-X strategy, any and and and the program tRNA for Jill on our up an call back our financial On clinical update ATYRXXXX, NRPX current synthetase handing Sanjay for before open corporate to will results our the preclinical program programs to Sanjay financial it

by be date or filings now call conference Harbor of to provision Sanjay. reflect law, remind statements on facts we these that risk facts statements and Safe as report except statements statements to management cause Pharma I information, call obligation not such differ and statements on our under the forward-looking of to change. events disclaims update to the Undue quarterly XX-Q. as only Private may risks uncertainties for and as Except factors issued Form the made XXXX. Act historical company's as made, circumstances statements. aTyr over are and circumstances. on statements, speak press required Please the can reports forward-looking company's turn placed by from questions in underlying most and the forward-looking are SEC like should will Before These materially these reliance XX-K forward-looking in statement responses the which I included future any recent annual they see on Form begin, forward-looking as this the to release Litigation Securities everyone that disclaimer Reform the well afternoon of of statements forward-looking to would in involve those results this actual in the

Dr. Sanjay Shukla

XXXX results Amidst readouts Thank you, included XXXX our you backdrop call. conference of quarter for Ashlee. everyone, productive We've company tracking obtained a on ILD in anti-inflammatory with was year discovery our the compared we XXXX. We for from in have study expanded program primary of move pandemic, in therapeutic We platform key that our and its advanced program a period candidate focused our synthetases. quarter. Phase Since enrollment this data therapeutic yield COVID-XX. advancements these from towards our readout to Phase tRNA antibody, in us lead and discovery research COVID-XX thank the clinical this We joining a year. with building this X the sarcoidosis anticipate Good progress mechanistic last insights XXXX. and from placebo. afternoon, we having expect biomarker for look patients for through in to in preclinical biology the COVID-XX XXXX lead discovery the achieved our by the sarcoidosis XXXX, X highly throughout a trial forward our and completed value to in ATYRXXXX cancer moderate pulmonary positive clinical signal fourth study candidate, deal data third kilogram in forward we lead for indication, report the patients or full quarter our significant trial we of XXXX's which of for with spoke severe patients pipeline We and and COVID-XX demonstrated remained released we patients to recently our complications. study our endpoint Xb/Xa and We're programs in improvement activity cohort aTyr, clinical pulmonary we highly proof-of-concept to preclinical for or novel The advanced our We're clinical from ATYRXXXX results we study XXXX in our gained patients met past initiated third program we anti-NRPX XXXX, for great or and effects respiratory from and and encouraged year. disease clinical and regarding programs milestones for lead severe our this expect lung in safety November, upon X-milligram completed as proof-of-concept hospitalized in several for per year. a of interstitial

animal overall compared demonstrated other positive We with cytokines XXXX consistent volunteers, in for those reported placebo. from Japanese X the trial in XXXX of XXXX a Patients chemokines, our milestone in Pharmaceutical, analyzed first in-patient trend and Phase key of ILD, which reduced proof-of-concept data for of improvement for Kyorin completed biomarkers payment implicated findings and from biomarker XXXX. the inflammatory in including XXXX study that provides healthy mechanistic a to ILD our treated development data sarcoidosis which is for models. with for visit also partner, the aTyr. last our are in COVID-XX. subject several its and commercialization triggered The Japan

or key Metabolism NRPX presented highlights a let research poster validating programs. demonstrated regulator and cell cells, Automation appointed and Aspartyl-tRNA leading NRPX identify DARS potential at advisor biology Medicine Her validating SLAS, Professor and Departments addition, anti-NRPX Cancer to focusing Microenvironment. research the cancer We a finally, to recent will and Association is recently Pathology for the describing and preclinical to synthetase, and from In discovery synthetase We tumor AARS to as of with Research our AACR on of investigate discovery poster for at novel the And researcher inflammation, Varner, suppressive XXXX accepted have in the the from programs. a further in fibrosis Symposia X or California company. the selected the our meeting. findings AARS of We Center natural presented X programs Conference San our support Diego on from development the Dr. biology DARS, synthetases immune program cell progression. the of signal expressed Keystone review of entitled X and solid macrophage that That poster at our International of platform. Moores presentation NK our announced Laboratory then transaction tRNA at a American Judith on preclinical scientific functionality fragments or we me the extracellular Tumor Exhibition, upcoming approach conference’s and Screening programs in biology. further here Alanyl-tRNA We the targets pipeline upcoming or for our tRNA NRPX tumor antibody as University killer antibody myeloid fragments, company's receptor and cancer, posters for in for synthetase Society at initially Cancer annual or

we're So past in will XXXX. the on Today, update pleased our an far therapeutic synthatese with what program, I we're a accomplished with financial year, and our off already program Jill of XXXX; for we've XXXX; thus biology. and will start position. very programs development NRPX preclinical conclude provide to clinical our lead great in candidate, with and tRNA our in and research efforts review our a

program. clinical our with begin Let's

stabilizing particularly the diseases. upregulated and thereby to downregulates role XXXX NRPX on reduce lung binds shown signaling prevent inflamed potential cells fibrosis, We preclinically patients. are downregulate NRPX XXXX as XXXX states. inflammation and cytokine has inflammation, progressive immune immune a and immunomodulator to inflammatory disease and morbidity been in in aberrant mortality treatment responses developing that and known We inflammation a severe selectively these is serving to is and to key first-in-class lung has normalize fibrosis. inflammatory for believe play and potential inflammatory alleviate is resolve lung and XXXX immune the enriched for to tissue. therefore, potential system, function chemokine

rare disorders the ILD, lung. that cause is a group Our focused progressive of immune-mediated lead of program on fibrosis

treatment formation characterized Our form ILD, formulation the long-term scarring cells indication of clumps other many ILD toxicity the of treated, corticosteroids not the irreversible these treating not immune can diminished inflammation do of include initial most sarcoidosis, in then and pulmonary but have the therapies granulomas lung If limited patients or and often are is to limited, current of lead options by serious which efficacy, with and lungs. it or -- immunosuppressive respond. inflammatory function

every and X Xb/Xa intravenously testing milligrams kilogram dosed of dose month months. trial per consists The XX polysarcoidosis doses double-blind X clinical The X of in XXXX. tolerability pulmonary the patients. is in or Phase doses trial of ascending randomized cohorts X safety primary X, trial objective for Our ascending placebo-controlled of multiple evaluate of placebo, sarcoidosis XXXX a and of is to multiple study

XXXX. Secondary potential the objectives steroid-sparing assessment include effects of of

pneumonia Based of we and lung the literature quarter binds from to is COVID-XX year. trial to sometimes fatal same of exploratory disease XXXX's a on lung and to our In mechanistically mechanism as provided respiratory downregulate enrollment recently action in expected assessed completed to relevant tissue COVID-XX us which function who rationale inflammatory serum we from placebo died receptor of to analyzed post not results very reported powered by We this while safety inflamed The biomarker. imaging, treatment. trial to. can positive dose with that pulmonary a tests its to data drug-related placebo. become were placebo, X-milligram significance and Patients the as did well top the can patients adverse a and patients in milligrams be the an per test in expression strong severe ventilation. has hospitalized, blind, we acutely of lung Medical of to response we complications. hospitalized XXXX that But evaluate an as also patient designed patients, and and intravenous the trial who require not reported dose in tolerated by that NRPX, many work treatment serious complete either XXXX the population. trial sarcoidosis, The of January, disease patients inflammatory interstitial other an lung, preliminary in the line cytokines placebo-controlled ability patients that in in compared This caused such whole COVID-XX for scientific days third -- in severe in addition pathology, complications, of mechanical followed XXXX function the study excessive demonstrating the identify intravenous investigate for to assessments in enrollment with to was XXXX assayed biomarkers inflamed of this overlap was serious initiated lead trial or This and shown experience primary observed trial form Phase for met and X a or single X or have groups randomized was In in placebo. this randomized or statistical X systemically X both of study and COVID-XX of study. kilogram events. respiratory XX compared from were of safe have serum generally single signals positive XXXX in to with and with safety, activity trial X was XXXX X no endpoint enrolled opportunity

X demonstrated median a X In XXXX dose. within were limitation to time a further days days the recovery, X kilogram This experienced the XX% patients per characteristics balanced milligrams recovery we X-milligram addition, receive of and/or of the disability in kilogram signal of of Patients All to a Demographic to compared received X at the compared placebo of of X-milligram the and the milligrams received patients recovery day of standard-of-care the the time compared we placebo, who XXXX the time time X-milligram recovery and is in proportion see the clinical by where in per activity baseline of patients of completed patients study of as at disability a XX% achieved of activities received through per in or patients to kilogram Today, recovery, XXXX which to Also, XX-day Patients treatment X will from of long-term -- cohort the with dose activity follow-up XX. analysis single and achieving placebo in kilogram remdesivir study evidence add X.X X-milligram who group improvement dexamethasone. median treatment group. included and kilogram these enrollment, of that recovery the determinants a group. have dose assessment day high-dose we study. week. treated still observed in days. kilogram no of had mostly this per X of per of for per

of a that and and to placebo cohort or randomization compared sicker important some hypoxia including in suggest groups more to associated patients of XXXX placebo. our randomization, population. with notice in did more with XX greater outcomes groups co-morbidities we our our These in treatment with the factors However, patients age the yielded patients treatment more imbalances risk multiple or COVID-XX over compared of are complications baseline severe worse patients

These detectable benefit XXXX some data overall very compared and were the patient the of analyzed study reported has improvement patients by the X-milligram biomarkers trend we elevated the encouraged see we patients data to improvement its repository. in in biomarkers Today, if patient from modest these the COVID-XX kilogram we these study, included for While that greater for serum per interested during saw that which reported support biomarkers of want compared an normal XXXX also key into disease its elevated a Upon inflammation had we order samples. and with biomarkers these several interferon SAA, compared details were findings. XXXX XXXX we placebo. results provide week, implications additional compared treated these reduced analyzed the clinical in to that where analysis, XX XXXX a those reductions and in placebo. protein-X. monocyte that both patients biomarker we significant with levels is greatest that which -- volunteer Furthermore, in treated The also cytokines to healthy provide including with anti-inflammatory provide with this pleased extent several treatment proof-of-concept benefit with as in collected inflammation greatest to the showed key were inflamed in of elevated including XXXX inflammatory numerical the XX effects that preclinically. mechanistic had were pathology in in patients in findings in XXXX the insight had downregulate Last and findings, Thus reduction very on cytokines. and as group in treated data were XX biomarker cohort, marker reduction that the seen elevations significant COVID-XX We're inflamatory chemoattractant assumed cytokines a additional animal fibrosis biomarkers, to of serum regarding aTyr improvement acutely these a clinical positive demonstrated had and XXXX patients that cytokine These impacting placebo. chemokines, we saw action. result trend interleukin-X XXXX to in levels further for first Notably, of consistent and what models. inflammatory particular, -- statistically our with sarcoidosis. A In gamma, in have we are same XXXX of has patients of and potentially an of indicating demonstrate these XXXX's treated a of patients we patients mechanism biomarkers or of had biomarkers XX% levels the treatment impact very overall validate to patients XX

to Overall, a results treatment lung which a profile the more milligrams to standard characteristics inflamed to to factors of demonstrate ferritin, of in inflammatory protein, risk treatment COVID-XX the as a C-reactive the and mentioned, groups worse with had XXXX continued the showed biomarkers, well from placebo. COVID-XX just care that enrolled we placebo including we're known greater very relatively seen from by this had this patients full outcomes. of disease recovery Patients of and D-dimer faster XXXX higher patient inflammatory population As kilogram indicating study, X Biomarker complications demographic and with the more adding encouraged XXXX's pleased in single cytokines baseline compared ops with XXXX diseases a favorable data at and in to XXXX safety study time the dose treatment by as confirms baseline. of levels compared associated arms.

with time severe a XXXX other that benefit anti-inflammatory the biomarkers, the groups observed inflammatory recovery steroids. findings we appears XXXX a was small demonstrate correlation given a drug including that top in clinical a of the the showing an treatment in therapeutic activity provide on and this as XXXX trend seen combined of ILD. even overall study, potential for added disease, and pulmonary levels benefits and higher baseline reduction These While sarcoidosis to lung of suggest have to further inflammatory when

our lead greatest XXXX readout in for sarcoidosis, we opportunity focus the pulmonary to We value. ability upcoming continue on believe and our has where near-term to generate study

development We forms currently of ILD. We available strategically potential efficacy of leader therapies limitations disease of most profile. treatments the need progressive for therapeutic this the for inflammatory a effect in new on and are area the the side treatments better and chose novel for based with

for validate mechanistic allowed and COVID-XX in trial hypothesis Our test our us to XXXX.

administration we the the the the the to backdrop being a that upcoming full this vaccines in have constantly landscape. sarcoidosis. of results Now pandemic, of and the Phase plans remain future Against are relative pandemic, evolving assessment of in readout trial, trajectory of on treatment of X assessed laser-focused we a COVID-XX evolving development

study the want results to X-milligram XXXX dose COVID-XX, and care standard we we about our study, in dose takeaways per perspective, pulmonary the pulmonary biomarker of possible, subtherapeutic the study including X, patients findings, powerful removing and program we to they our if top the clinical which doses sarcoidosis upon tapering the the steroid to work fundamental that By sarcoidosis X-milligram doses X regularly XXXX study on XXXX administers and X in sarcoidosis. that of Throughout models, clinical As we want trial steroid. we a pulmonary the and, in altogether the biomarkers, to to of cytokines are We current include in use, placebo. to From animal in that kilogram of think downregulated have as in note steroid was clinical some signal ILD, hypothesis the highlight mechanistic program lead relate a this steroid monthly in steroid. reported evolved encouraged our seen showed activity trial the a to single to down of dexamethasone, translational that ILD findings COVID-XX and it the which was a a evaluating compared design, established. the administered reduces highly comes compared while same it of COVID-XX trial of in When the in study. main in dose

XXXX literature of paper in SAA a that SAA, small that other the sarcoidosis, significant implications recent rather a Netherlands, levels We also expect of of the third just by importance not year. ILD. Lung Medical but that finding Center suggesting this at SAA leading to statistically in to marker in from in We study. report Excellence forward the this this growing Interstitial Disease of reiterate a excellent results XXXX reduction patients sarcoidosis, look also has which supports as published study evaluate the with in a of we pulmonary sarcoidosis, in quarter including had researchers fibrosing of the

turn renal, its is let's may where which breast, is expression with research NRPX our in to current target. continues potential Now linked different tumors, to solid in Antibodies cancers on pathways compelling is outcomes producing to In areas many selectively NRPX the inflammation. may resistance advance in to have include High can first therapeutic therapies. patient our lung antibody worsen potential pipeline, signaling various and In implicated. some aggressive few. drug upregulated name such NRPX that to a block therapeutic cases which is NRPX ILD. cancers, NRPX oncology of cancer, toward program, starting as NRPX a and

aggressive explore of we tumors, on continue a to the to of microenvironment the expression progression each of of wanted immune and of these As determine in tumor NRPX NRPX the cells. role on the certain role variety its we cells and

progression. poster cancer proliferation was that from the cells regulating MDSCs breast cell or suppressor macrophages immune mature implicated lines tumor-associated These Symposia, dendritic and virtual generated Further that T triple-negative cells showed expressed presented activation. MDSCs, on key in TAMs or Keystone included and recent cell TAMs myeloid-derived cells. at research demonstrated NRPX cancer Our and highly suppressed

key NRPX NRPX that support are a tumors have is target as regulation validation potent possibly their pleased further suppressive the time of These potential of cells regulating regulator the very NRPX the the through progression therapeutics, we're and highly for microenvironment, cells important findings provide expressed and So microenvironment. progression implicated immune of solid a as on to immune first of tumor tumor that cancer the for in demonstrated metastasis. the tumor of of

the at cancer, a meeting continued cancer of target selectively is solid medical breast Mercurio, lead ligands. lab NRPX we panel of that other the annual functionally breast has cancer progression are compelling from responsive in validated. As of specifically organoids to the NRPX shown on in aggressive to humanized other we and in the This highly collaboration we primary of to vitro interaction tumor at XXXX triple-negative available one our not blocks the where patients developed University showed its and tumor this explore the and and that of aggressive monoclonal models and is that XXXX chemotherapy of ILD to Arthur his school. many sensitivity various the IND-enabling to antibody XXXX candidate based to effects NRPX increased microenvironment tumor between implicated. at and human-derived potential expressed, scientific This data and look advance models role currently then, year our of distinct treatments. the one antibodies We we a and inhibitory have VEGF domains selected data NRPX becoming The in fully have and that presented models candidate. NRPX, in cancers Since certain of demonstrated been its AACR Dr. tumor Massachusetts increasingly with signaling importance in advisers generated VEGF, activity last extremely data an be where preclinical in

annual meeting. AACR will posters this Next month, we at X present year's

posters posters findings preclinical research AACR. presented regarding findings to poster our AACR lung these looking these cancer. at these last details cancer, we breast second forward the research from One new year builds at while the in We're presenting that providing of upon and in presents additional

related selected immune-needed discovery pursuing these fragrance we their role have in NK regarding findings. We new X tRNA demonstrate program, some AARS, X synthetases fragments AARS these the And and important January. innate transformative synthetases, at Finally, to Most utility tRNA and focus which research our synthetase in for demonstrate targets new discovered findings have activities information We the to update tRNA responses targets disease. our the maybe therapeutic receptor of we for I its forward AARS provide DARS. fibrosis pathways expect these cancer to receptor on particular, identified and DARS, in These tRNA to But has notably, key will pipeline, treat aTyr presented for now platform biology. SLAS recently our and a announced may a more at development ability from receptor on we biologic synthetase targets. look poster to these receptors relevance these binding that synthetases HARS, cell new in initially role We important determine X yielded further NK and SLAS potential future. exploring discovery cells wish is to disease vertical of to that tRNA have findings immune that targets in generate In pathways validate these DARS. therapeutics inflammation. and synthetases oncology. and targets of immune cells, new and findings in findings, to Based play biology presented the drug to

of compositions beginning promise a the and and unlocking As are patented. We aTyr's believe gene potential XX only from consists XXX portfolio covers intellectual protein this of all novel at families protein the over derivatives we tRNA reminder, biology platform. property with synthetase

like to financial So turn it Chief with to results. Broadfoot, Officer, Financial to that, over our our review I'd Jill

Jill Broadfoot

Thank XXXX. We're you, $XX.X in report for revenues Sanjay. to proud total million

primarily we XXXX and Our for revenues, from collaboration which Kyorin received Pharmaceuticals. agreement consisted license revenues of

XXXX, license agreement we of received and January ILD upfront commercialization $X Kyorin, an in in million aware, you're Japan, XXXX a into entered and As development which for payment. collaboration with the for we for

we X million January Japan In Kyorin milestone milestone in was in XXXX. payment a XXXX $X that addition, a in Phase received achieved December by for

in million million for and ended December activities COVID-XX complications. XXXX of years and long-term XX, both expenses our ended and $XX.X XX, expenses guidance From at were exceeding administrative programs. XXXX sheet the due November expense clinical consistent of XXXX were with million ending progression we for $X.X the $XX.X million respectively. further we XXXX, guidance the and and primarily with years $X.X a December million previous respectively. with in On was respiratory General $XX with in than The positioned side, our periods are year patients development increase cash the severe all year and lead for loans. ended the XXXX, the our sarcoidosis between to balance previous research we perspective, Consistent and in greater And cash, the development and well $XX investments. cash, equivalents repaid XXXX, now million of pulmonary

in LLC. gross from offering Kyorin Aspire We raised approximately purchase with In addition, million expenses milestone in proceeds our year-end, in $XX since million $X at-the-market deducting and from raised and gross our over approximately agreement we've raised million Fund, cash $X.X proceeds commissions program million in addition offering the before to receiving $XX.X payment. Capital

XXXX our programs. expenses to we continue While XXXX increase and in cash, we development this giving won't do move discovery ending we and our develop year as guidance to and expect be research for specific forward

like Sanjay I'd to call Now open the before back up turn to over we to it Q&A.

Dr. Sanjay Shukla

Thanks, what our in we are very progress. XXXX of Overall, significant we're achieved pleased proud and Jill. with

readout for sarcoidosis potential in in a proof-of-concept XXXX We pulmonary have sight.

our by results Now biomarker proof-of-concept COVID-XX from a our from patients. supported in trial mechanistic

for had million our for to XXXX use year XXXX that brought in cash in already already milestone $XX through of a the first a million studies for We're this the we in tRNA deal year have a in in to target your $XX come. the eliminate. continue with a off discovery time, to take major Japan X will support. IND-enabling been XXXX, in that Jill ILD we've interest, future. we appreciate continued be license with this updates and started and Look great year-end lead for to guidance vehicles, with undergoing anti-NRPX cancer. position, your have to previous momentum And identified year. program preclinical to receptors of payments the start our your able structure equity synthetase that and has onerous programs We At exceeded for and quarter Kyorin, an payments. look be available We antibody, XXXX, providing raised and in ready debt over to partnership I in our we've questions. explored. happy forward We We We

Operator

Instructions]. [Operator

question Oppenheimer. of Hartaj the Our from Singh come will first from line

Hartaj Singh

you're be enabling to is indicated, the stage pretty your had Great. cancer, board, you in what you non-small done? One which is therapy breast to advisory more usage on addition cell heavy-duty it see question combination do work is on And presenting of would that, you non-small follow-up of IND sort follow-up lung Board, at, it you'd too. as lung monotherapy, this Where of XXXX? cell IND-enabling more and cancer, the a data I be think cancer, I then just scientific going initial cancer on breast your a got quick And as area. once on XXXX, mean, oncology your Sanjay?

Dr. Sanjay Shukla

Yes.

much for XXXX efficacy model. stage in we So very in-vivo are of that this year, looking at

and year-on-year cancer. data as already solid neuropilin out in point you different new models coming with triple-negative we've out, cancer tumor AACR now seen additional data lung testing And implicated. data of breast So good is where in now

is of or conjunction get also year, we positioned monotherapy So in really into look that to used But to we're of few models. efficacy once as be tumor more will us able the determine this towards a out, the second half best way, efficacy animal for or you patients. the a which environment continuing a take unlock therapy other to tumor move whether state in indication data look of be we'll top and at to But with learn even therapy not as on chemotherapy. another point along into best our be we'll at

oncology all the those also will over to this So laid course really want is in out we bring which of expertise space. of in why here answers be the year,

submission, of meantime, they Dr. there's work complete someone as to and side last guides regards And I experts the and Mercurio their previously like tox say quite also for even the with this to Dr. on biology, added bit stay to us. that would In prior Varner IND tuned. serve so year, have great we a the

to used XXXX whether or environment. best from then can also it's we as We're ways. combination. testing tumor monotherapy that it as about which where and continue or a demonstrate not will be We learn a And best more learn used, both standpoint,

Hartaj Singh

then, you chronic it therapy, And as right, rate-limiting give think made trial the Yes. COVID-XX steps Sanjay, designed I maybe the which of that once. the point one could where is XXXX for only you

be to assume be in of antibody given in I such ways this XXXX, cancer For correct? that, kind would acute that setting, designed

Dr. Sanjay Shukla

But I that think in that's yet you to about how determined. Yes, that here targeted. are biologics general, in antibodies be general, is, in think

targeted to is meant of be to that clinical be that we a but the in certainly The yet manner we therapy. relative worked PK here before out, a and into So will it's have which dose move mapped we indication. out

Hartaj Singh

could an us Can on And we of update this just of hitting Great. what maybe And you to is sort next as question or be Behring next could see year milestones then then collaboration. year? kind my also, there? give last CSL the steps just when

Dr. Sanjay Shukla

Yes.

DARS. those that's that able aTyr So been from a over where and around our findings. findings AARS back the of And here really oncology we've areas collaboration. work came that that out owns the fence bring Much collaboration of to of

with area -- sort have. forward on internally we doesn't now, side on them have the fall excited to really we right of really regards really moving focusing we're these a our that I of within of So With as CSL, here. sort CSL expertise to further they fence think of are therapeutic work

So here. moving with cell those NK of have activities are we benefited forward now as these really some internally findings turns And it us. out,

Operator

will from Pantginis next question the H.C. Joe line Our of from come Wainwright.

Joe Pantginis

Sanjay, my for XXXX. going to on questions are just now focus continuing profile the to build right

just visibility SAA And especially ILDs you able for SAA? implications then other on we for especially what guys as when for clinical are the ILDS? be you of to the into ability announced, going related, the to quarter update based you think biomarker sort it's have get as since of trial sort So mentioned third well, see we as sarcoidosis, we towards has might towards protocols additional do look to built data the that

Dr. Sanjay Shukla

study, but assay-able advantage there lungs, if tend of they thing coming less patients that's the of, lung, to the remember of, be they're our from biomarkers. so In no we blood. able their inflamed can take in Joe, in also Yes. severely systemically. presenting readily in These with severely to ILD case locally not the you unique so are a lot XX by about to elevated been serum what that one biomarkers inflamed highly we've is assay just study only will, in patients, pulling COVID-XX

would do as this don't is best really biomarker a patients a the do to really to and grab perspective, we bronchoscopy tissue lungs, is that much. from like from which -- the try way So to

we ILD the this ILD think we the able there that sense, over fluid in we the very let's mechanistic BAL also proof-of-concept literature, assaying to same are looking there patients. ones lungs ILD right in a COVID-XX, impact cytokines Nonetheless, in elevated trickier systemic from demonstrate at looking biomarkers but are is in of in that that highly were the little and we at that what's bronchoscopy, understand already literature patients. the the literature So and carries know the sensitive

of most more here the good steroids that on being at course, In lung really rely sensitivity clinical the gives bronchoscopy, think out I confidence of that's be tendency in it about looking anti-inflammatory cytokines leading biopsy chemokines there's bit when we've I is reduction these and a a think impacts the in that we are not that here, directly think experts. think trial and important serum our the really, the of change here we some will findings, study. probably we see to an ILD. I much us involved mainly assay able the biomarkers, through Europe, So of with But so but to got greater pathology in U.S. and little of And that

real to. think that's attention pay activity the endpoint to I

Joe Pantginis

as And well. that clarification it. Got

know just but this indication, them, study? would was we with I keeping any So you the should curious if updates say Kyorin I you around ask -- obviously,

Dr. Sanjay Shukla

group their Yes. Kyorin just are that do. I and they say planned. progressing PR that would IR own as things has

a and our not expect a on do plan to of we number can't to that be get in delays next But that. with on started, with clinical any we centers I worldwide So experts them. or with say working and any anticipate for there won't we sarcoidosis, out hiccups are join will track teed development they I are the are what up trial, to will registrational put that will trial, speak which have we Kyorin

Joe Pantginis

Obviously, ever-changing last it. Got Got a with potential then the maybe the regarding regard steps. you that stab it. And to, want what is about move landscape pretty to comments you I tree, take my at is think, and evolves alluded next question, fruit it's an your whether decision especially quick to because therapeutic but of low-hanging you can as to landscape forward? your it sort decide COVID-XX

Dr. Sanjay Shukla

on a even are also our -- lot is I in confounder There And Well, potentially we we here who key think not a the our having is the that are a thing vent, to trial. the even was not hospitalized potential but utility, only data. experienced patients in greater vent. recently of have seen those that on dexamethasone that

that showing presented, of here. you As additional readouts dexamethasone, When and we've utility. it the the shown out, and that biomarker our look clinical beyond drug turns is the apparent talked above and benefit today is about at very we've XXXX we

a COVID-XX, just millions a that of yet. resistant don't sensitive to with might don't But data are low-hanging pathology we pulmonary epidemiology that I that that of data. at of Our tens know that be fruit. a know be we patients, view it is know. Is and also in the our our that or potentially COVID-XX from know could population if millions a dexamethasone of We do can now there's patients? sarcoidosis drug looking XX,XXX is patients impact What preclinical there's this patients, that XXX,XXX sensitive population cohort

think squarely landscape to about we potentially biopharma. we really this coming, the ever-evolving work thinking So impact to very, leader we're an in here as sarcoidosis and that are very ILD have make with I worldwide on are excited readout near-term and any that compared the fact focused

Operator

Instructions]. [Operator

ROTH line the of come question Our will Zegbeh from Capital. Jallah from next

Zegbeh Jallah

I think just I questions. a couple have different of

kind be will said, question. off be little COVID learn kind might just think of landscape resistant. to evolves the you're the clinical I of that with know, patients somewhat piggyback see I the bit be unable more Sanjay, how a trying or and like first those treated you of dexamethasone to And about

as to the is would data think Do move will think study pulmonary encouraging. with interesting actually your sarcoidosis that I just well? so And be really your decision forward it influence COVID if you

Dr. Sanjay Shukla

mind So that does is right? that we your saw if question, our Is Zegbeh, sarcoidosis, for in change good COVID? data

Zegbeh Jallah

importance have well especially that higher going Yes, dose? you're since to and data see be to as X-milligram better the able of

Dr. Sanjay Shukla

highest a that's So good very the in point. testing We're sarcoidosis. dose

sort that into. cash. before, patients, see So I we've we a company, to how dose-dependent we to sarcoidosis Phase run and We look, X that would were our number very of X move as understand about love I a certainly, if if careful all we small manage to been improvement be indications we of this said trials, -- could a we encouraged think the in try pharma, a large we there's

think of a useful now, try generate interstitial programs a milligrams Right think be pneumonia. can we to term. drug isn't the be COVID, there. also the acute acute there with indication. that lot movement potentially We an shown landscape I in into solid We've out could given near used move in value our Frankly, could there any in X

alive. eyes, keep a But space throwing as just -- opportunity, multi chronic an where drug is viral conditions dearth them commercial green we that be And ICU is, then etiology. demonstrated safe want well trying have other treatments. acute COVID thing this really treatments, last in our treatment that steroids, see you but as a steroids etiology market, or market, I'll ILD we've at a of And think I a you're of because like there's good the used useful, several can to the is of environment where a a where really, chronic add good a the treatment, pneumonia billion-dollar built in off could whether patients in patients ILD to get be these the here ILD. setting, really you're really

with the -- to -- the in here, of on PI, wanted steroids the get ILD the patients, we're because steroids the So compete to off there. defense wants side we everyone

now some a us. opportunity daylight it's can some see of with And biomarker huge for we this data, really think I here.

Zegbeh Jallah

And data Sanjay, that expectations some biomarker definitely positive the does readout. for set agree the

to going if the wanted points. have a any of so what data something could the be Is know to that's the And readout, pandemic missing of up regarding there impact just as the had been? just heads

Dr. Sanjay Shukla

Yes.

keep patients the bit here impacts because a for certain function missing may things kind there. under every key some restrictions, testing example, have as centrally blowing We're lot can visits hospitals getting kind think minimize little -- is are of sort lot at of the hospital, want don't say as of pulmonary air be -- some COVID possible. certain, have there. want would of I at a some where there trying you're aspirating center of patients you patients a I They to look things points can that different. you safe. to in where data here and much you There

not you trying of problem. things. But another there local replacement are us. might are PFTs to testing. might of it's be to pulmonary prioritizing these we sort endpoint Pet we we're basically now? scans So thing -- all scans Pet cover an where where sort That they don't report area It's right institutions how think exploratory to function see going around slight -- a use it's a an not be for

patients be So there you there. be some -- could could

We this preserve also from have steroid-sparing to really, perspective, there, that key is missing most a and the we think really here thing the data But ability trial. a safety I data the from from have of too.

Zegbeh Jallah

And Kyorin with and study, participation then point another was in study. made large global X a the you Phase perhaps

move readout? just wondering was you I this your study next into when might so And after data

Dr. Sanjay Shukla

And been good like trial on this for regulators, have need what We'll the the and year. sit of drug, next after Phase down trial good, ILD assuming our be look already have about trial with alignment feel forward. like is X as that nature a to good in feel real relative moving a start readout previously on there's right leading -- into ILD study the development we'd of the trials in the We'll we we the now. We patients this company though that now, as also we readout moving and run based space. probably these as should know right that rationale

So what this can't you quarter give it's that because we But a to other to next we into little would premature just guidance with for trial potentially next and to on partners that be and that. yet think Kyorin trial move do would would looking I year. looking move I into year. we start look it be

Zegbeh Jallah

But Perfect. questions it you you list ask. And my like sounds had just mentioned, actually working yes, on I quarter, was with I are quarter. XXXX, studies going to on the IND. it partnerships, of to specific preclinical regarding tox on the squeeze the you

early-stage something talked just sounds allocating that can you think early, independently. want partner, collaboration on you Or want of might I that but capital? your that you at how out execute Is about So cash you partner I'm CSL. more a to and came work it will perhaps, the about with do looking that to you're balance worried your like

Dr. Sanjay Shukla

compared mean, about year where to just had X ago Yes. a program. I we really

have we Now X.

to about have that's We have clinical program a readouts.

only that's these cells. side, program fragments exciting work. NRPX natural with found have now We And have but new antibody not a in X we've then programs, the killer on got that we IND-enabling balanced discovery preclinical

happen. to on is a of something business to our look have partnership at own. early. can if opportunities in Kyorin now we all thing great development I conversations. guide of regards more have we and quite accomplish kind we So The It's when have those with don't to to can sort really came

at did beginning XXXX. of I was we think transformative a that rather deal the

potentially around like out think our exciting new an they're in discovery earlier options. more with this are now data I If little we for have natural them. is reach our we to BD interested more to partners and neuropilin-X, to team oncology also anchored to have Now If data will sets options. present interested and bit cells, interesting programs more opportunities in target are a going killer

certainly, So options more aTyr. lot had really a we've previously at really, than this year ever

verticals, for that right and pipeline have we clinical, partners, to preclinical all if shareholders. discovery, here look a do -- We clear X will for us engage and which of to ourselves potentially the has clear it's thing

Operator

turn questions would for just from the it And any closing to further I over any remarks. I'm showing not Sanjay queue.

Dr. Sanjay Shukla

to certainly for of had information their year. this everyone lot through interest, thank I go Well, a

of number to interest, I Thanks I have in think in for excited, for everyone we you that's these you very and trial. around on, readouts our speak important year things particular, for thank us. reflective that we here the their the going future. up-to-date and We're again. in keep will sarcoidosis

Operator

gentlemen, conference this and concludes call. today's Thank participating. Ladies for you

now may disconnect. You

aTyr Pharma (ATYR) 24 Mar 212020 Q4 Earnings call transcript